首页> 美国卫生研究院文献>Scientific Reports >Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus
【2h】

Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus

机译:可溶性尿激酶受体(suPAR)预测有2型糖尿病风险的患者存在微量白蛋白尿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Early identification of patients at risk of developing diabetic nephropathy is essential. Elevated serum concentrations of soluble urokinase receptor (suPAR) associate with diabetes mellitus and predict onset and loss of renal function in chronic kidney disease. We hypothesize, that suPAR may be an early risk indicator for diabetic nephropathy, preceding microalbuminuria. The relationship of baseline suPAR and incident microalbuminuria was assessed in a prospective long-term cohort of subjects at increased risk for type 2 diabetes (TULIP, n = 258). Association with albuminuria at later stages of disease was studied in a cross-sectional cohort with manifest type 2 diabetes (ICEPHA, n = 266). A higher baseline suPAR was associated with an increased risk of new-onset microalbuminuria in subjects at risk for type 2 diabetes (hazard ratio 5.3 (95% CI 1.1–25.2, p = 0.03) for the highest vs. lowest suPAR quartile). The proportion of subjects with prediabetes at the end of observation was higher in subjects with new-onset microalbuminuria. suPAR consistently correlated with albuminuria in a separate cohort with manifest type 2 diabetes. Elevated baseline suPAR concentrations independently associate with new-onset microalbuminuria in subjects at increased risk of developing type 2 diabetes. suPAR may hence allow for earlier risk stratification than microalbuminuria.
机译:早期识别有发展性糖尿病肾病风险的患者至关重要。可溶性尿激酶受体(suPAR)的血清浓度升高与糖尿病相关,并预测慢性肾脏疾病中肾功能的发作和丧失。我们假设,suPAR可能是在微量白蛋白尿之前糖尿病肾病的早期危险指标。在前瞻性长期队列中评估了2型糖尿病风险增加的受试者的基线suPAR与事件性微量白蛋白尿的关系(TULIP,n = 258)。在患有明显2型糖尿病的横断面队列中研究了疾病晚期与白蛋白尿的相关性(ICEPHA,n = 266)。较高的基线suPAR与罹患2型糖尿病风险的受试者中新发微量白蛋白尿的风险增加相关(最高suPAR与最低suPAR四分位数的风险比5.3(95%CI 1.1-25.2,p = 0.03))。在新的微量白蛋白尿患者中,观察结束时患有糖尿病前期患者的比例更高。在一个明显的2型糖尿病患者中,suPAR与蛋白尿持续相关。在罹患2型糖尿病的风险增加的受试者中,基线suPAR浓度升高与新发的微量白蛋白尿独立相关。因此,suPAR可能比微量白蛋白尿允许更早的危险分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号